Phenom Named Strategic Leader in 2024 Fosway 9-Grid™ for Talent & People Success
Positioning Recognises Phenom’s Impact on Helping Europe’s Largest Companies Solve HR’s Biggest Talent Management Challenges
Phenom has been named a Strategic Leader in the 2024 Fosway 9-Grid™ for Talent and People Success, a testament to the value delivered by the AI-powered Phenom Intelligent Talent Experience platform, which makes new employees productive faster, enhances development and increases retention.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241010930504/en/
Phenom has been named a Strategic Leader in the 2024 Fosway 9-Grid™ for Talent and People Success, a testament to the value delivered by the AI-powered Phenom Intelligent Talent Experience platform, which makes new employees productive faster, enhances development and increases retention. (Graphic: Business Wire)
Fosway Group identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sophistication to consistently meet the needs of complex enterprise-scale customers. Strategic Leaders are also recognised by Fosway Group for having strong market performance and customer advocacy; as a result, they are frequently selected by such organisations and consistently meet their needs.
From labour shortages to changing skills and emerging technologies, the European job market continues to transform. To navigate this, talent management professionals, HR leaders and HRIT teams must collaborate to make new employees productive from day one, provide continued development opportunities, identify and fill skills gaps and encourage long-term retention.
“As European organisations wrestle with how they become more skills-based, they have been looking at how their tech stack solves that problem,” said David Wilson, CEO and founder of Fosway Group. “With their roots in skill-based hiring and their growing specialist capability around internal mobility and skills intelligence, Phenom has been well placed to provide a springboard to those answers for enterprise buyers. And their growing service and platform maturity has been pivotal in making them a Strategic Leader for talent experience on the Fosway 9-Grid™ this year.”
Phenom’s solution for talent and people success centers around delivering hyper-personalised experiences for employees, their managers and talent management. These experiences are enhanced with X+, Phenom’s Generative AI that is purpose-built for HR, to support key areas including:
- Pre-boarding: Provides a streamlined, transparent and easy experience that makes a lasting positive impact for new employees.
- Onboarding: Shortens time to productivity for new employees and automates tedious, manual tasks for HR teams.
- Talent Marketplace: Gives employees visibility to internal job and growth opportunities, as well as refers quality talent for critical roles.
- Career Pathing: Helps employees discover their next internal career move and the skills needed to get there. X+ provides an always on career coach that responds to their questions with personalised development plans.
- Cross-boarding: Supports employee transitions to new positions and teams.
- Workforce Intelligence: Identifies skill and competency gaps and insights within each department and at the enterprise level.
- Learning and Development: Educates internal talent with personalised courses to support upskilling and reskilling based on their projected career paths.
- Mentoring: Empowers and supports employees throughout their career journey by connecting them with best-fit mentors.
- Gigs: Provides real-world experience through short-term work and project-based tasks allowing employees to develop their skills.
- Employee Resource Groups: Fosters engagement, community and a sense of belonging.
- Offboarding: Streamlines experiences for employees leaving the organisation.
“Phenom’s positioning is a testament to our ongoing innovation and helping European organisations embrace a skills-based approach to talent management, growth and retention,” said John Deal, Sr. Director, Product Marketing at Phenom. “As Europe contends with an evolving workforce landscape, it has never been more critical to leverage intelligence to enable smarter and more impactful career development, upskilling and workforce planning decisions.”
Phenom’s placement also complements the company’s four-year positioning as a Strategic Leader in the Fosway 9-Grid™ for Talent Acquisition, showcasing the end-to-end benefits of using its full Intelligent Talent Experience platform. Over 700 global and diverse companies are using the Phenom platform to help:
- Candidates find and choose the right job faster.
- Employees develop their skills and evolve.
- Recruiters become wildly productive.
- Talent marketers engage with extreme efficiency.
- Talent leaders optimise hiring processes.
- Managers build stronger-performing teams.
- HR aligns employee development with company goals.
- HRIT easily integrates existing HR tech to create a holistic infrastructure.
See why Phenom continues to be recognised as industry leading, book a demo.
Click here for a personalised demo of Phenom’s Workforce Intelligence solution to learn more about how to set your employees up for career success.
About Phenom
Phenom has a purpose of helping a billion people find the right work. Through AI-powered talent experiences, employers use Phenom to hire and onboard employees faster, develop them to their full potential, and retain them longer. The Phenom Intelligent Talent Experience platform seamlessly connects candidates, employees, recruiters, talent marketers, talent leaders, hiring managers, HR and HRIT — empowering diverse and global enterprises with innovative products including Phenom X+ Generative AI, Career Site, Chatbot, CMS, Talent CRM, X+ Screening, Automated Interview Scheduling, Interview Intelligence, Talent Experience Engine, Campaigns, University Recruiting, Contingent Talent Hiring, Onboarding, Talent Marketplace, Workforce Intelligence, Career Pathing, Gigs, Mentoring, and Referrals.
Phenom has earned accolades including: Inc. 5000’s fastest-growing companies (5 consecutive years), Deloitte Technology's Fast 500 (4 consecutive years), five Brandon Hall ‘Excellence in Technology’ awards including Gold for ‘Best Advance in AI for Business Impact,’ Business Intelligence Group's Artificial Intelligence Excellence Awards (3 consecutive years), and a regional Timmy Award for launching and optimising HelpOneBillion.com (2020).
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, X, Facebook, YouTube and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241010930504/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK™,a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press release
- ALYFTREK™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies - - In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV1 and further decreased sweat chloride compared to TRIKAFTA® - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and t
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press release
- Approximately 300 more people with cystic fibrosis in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
Andersen Global udvider sin ekspertise med tilføjelsen af Valora20.12.2024 17:07:00 CET | Pressemeddelelse
Andersen Global fortsætter sin udvidelse af servicetilbud gennem en samarbejdsaftale med Valora, der er en uafhængig virksomhed med speciale i levering af skræddersyede løsninger til både private og institutionelle kunder globalt. Valora har kontorer i Miami og Raleigh og desuden global tilstedeværelse i Den Dominikanske Republik, Storbritannien og Caymanøerne. Valora blev grundlagt i 2011 af partneren Luis de Leon og tilbyder et stort udvalg af tjenester, blandt andet værdiansættelse, performance, regnskab og administration, global enhedsstyring, fondsvirksomhed og andre skræddersyede løsninger. "Et samarbejde med Andersen passer godt til både vores kunder og vores team," siger Luis. "Synergierne mellem for vores servicetilbud vil sætte os i stand til at levere omfattende og integrerede løsninger med stadigt stigende global rækkevidde." Global Chairman og CEO for Andersen Mark L. Vorsatz udtaler: "Valoras team og virksomhedskultur er, sammen med deres fokus på det praktiske, et godt m
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom